X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-10 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale+OE | $6.43 | -124,727 | 436,422 | -22% | -$802,494 | |||||
| D | 2026-04-10 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale+OE | $6.43 | -124,727 | 436,422 | -22% | -$802,494 | |||||
| D | 2026-04-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $4.46 | -200,000 | 1,136,410 | -15% | -$892,000 | |||||
2026-04-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $49.89 | -2,597 | 125,694 | -2% | -$129,562 | ||||||
| D | 2026-04-10 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.56 | -3,125 | 29,375 | -10% | -$8,013 | |||||
| M | 2026-04-04 | MESO | Mesoblast Ltd | George Gregory | Dir, 10% | P - Purchase | $1.44 | +7,910,962 | 33,910,962 | +30% | +$11,396,977 | |||||
2026-04-08 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $82.58 | -20,000 | 1,132,987 | -2% | -$1,651,664 | ||||||
| M | 2026-04-04 | MESO | Mesoblast Ltd | George Gregory | Dir, 10% | P - Purchase | $3.15 | +8,305,962 | 33,910,962 | +32% | +$26,135,093 | |||||
| D | 2026-04-08 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $15.07 | -22,564 | 273,654 | -8% | -$340,039 | |||||
2026-04-08 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $14.85 | -10,000 | 1,512,058 | -1% | -$148,500 | ||||||
| M | 2026-04-08 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $16.50 | -620,133 | 3,935,608 | -14% | -$10,233,811 | |||||
| DM | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale+OE | $6.66 | -26,271 | 338,568 | -7% | -$175,067 | |||||
| DM | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale+OE | $6.66 | -26,271 | 338,568 | -7% | -$175,067 | |||||
| DM | 2026-04-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale+OE | $6.65 | -206,782 | 316,483 | -40% | -$1,374,493 | |||||
| DM | 2026-04-09 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale+OE | $87.47 | -10,264 | 51,542 | -17% | -$897,782 | |||||
| M | 2026-04-08 | EXOZ | Exozymes Inc. | Korman Tyler Paz | Chief Scientific Officer | S - Sale | $10.28 | -1,500 | 729,123 | 0% | -$15,424 | |||||
2026-04-09 | GLUE | Monte Rosa Therapeutics, Inc. | Nickson Philip | Chief Business, Legal Officer | S - Sale | $17.69 | -5,845 | 55,000 | -10% | -$103,413 | ||||||
2026-04-08 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $24.83 | -5,165 | 183,231 | -3% | -$128,247 | ||||||
2026-04-08 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $24.83 | -8,722 | 245,222 | -3% | -$216,567 | ||||||
2026-04-08 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $24.83 | -10,132 | 254,439 | -4% | -$251,578 | ||||||
| DM | 2026-04-07 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale+OE | $13.19 | -19,517 | 213,867 | -8% | -$257,498 | |||||
2026-04-08 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Chief R, D Officer | S - Sale | $5.40 | -1,134 | 94,827 | -1% | -$6,124 | ||||||
| DM | 2026-04-07 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.38 | -7,875 | 29,375 | -21% | -$18,758 | |||||
| M | 2026-04-06 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $14.65 | -120,595 | 2,180,518 | -5% | -$1,766,839 | |||||
| DM | 2026-04-06 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.34 | -69,061 | 434,188 | -14% | -$990,503 | |||||
| D | 2026-04-07 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.10 | -40,000 | 906,556 | -4% | -$124,000 | |||||
2026-04-07 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.10 | -30,000 | 6,229,863 | 0% | -$93,000 | ||||||
| D | 2026-04-07 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance, CAO | S - Sale+OE | $60.00 | -3,000 | 28,975 | -9% | -$180,000 | |||||
2026-04-07 | MGTX | Meiragtx Holdings Plc | Naylor Stuart | CHIEF DEV. OFFICER | S - Sale | $9.36 | -27,661 | 668,505 | -4% | -$258,907 | ||||||
| D | 2026-04-06 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $63.50 | -10,000 | 767,780 | -1% | -$634,982 | |||||
2026-04-06 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $5.69 | -55,000 | 340,106 | -14% | -$313,137 | ||||||
2026-04-06 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | Pres, CEO | S - Sale | $9.16 | -72,559 | 1,001,263 | -7% | -$664,350 | ||||||
| M | 2026-04-02 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $17.10 | -849,257 | 4,555,741 | -16% | -$14,518,963 | |||||
2026-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale | $24.58 | -30,078 | 1,150,205 | -3% | -$739,317 | ||||||
2026-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $24.58 | -6,700 | 102,735 | -6% | -$164,686 | ||||||
2026-04-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.58 | -3,242 | 51,171 | -6% | -$79,688 | ||||||
2026-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $24.58 | -5,956 | 109,711 | -5% | -$146,398 | ||||||
2026-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale | $24.58 | -11,810 | 218,406 | -5% | -$290,290 | ||||||
2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Malamut Richard | Dir | S - Sale | $20.92 | -590 | 28,462 | -2% | -$12,340 | ||||||
2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Dir | S - Sale | $20.92 | -558 | 204,099 | 0% | -$11,671 | ||||||
2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Pauls Matthew | Dir | S - Sale | $20.92 | -786 | 15,150 | -5% | -$16,439 | ||||||
2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Greenleaf Peter | Dir | S - Sale | $20.92 | -797 | 24,681 | -3% | -$16,670 | ||||||
2026-04-02 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $8.01 | -6,500 | 151,588 | -4% | -$52,065 | ||||||
| D | 2026-04-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $35.00 | -3,472 | 75,556 | -4% | -$121,520 | |||||
| D | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $84.84 | -5,500 | 208,398 | -3% | -$466,619 | |||||
2026-04-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $85.01 | -2,000 | 177,371 | -1% | -$170,020 | ||||||
2026-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $3.87 | -11,511 | 472,549 | -2% | -$44,548 | ||||||
| D | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | CEO | S - Sale+OE | $24.10 | -14,229 | 19,561 | -42% | -$342,854 | |||||
2026-04-01 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Chief Medical Officer | S - Sale | $31.05 | -1,000 | 68,747 | -1% | -$31,050 | ||||||
2026-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $58.43 | -2,250 | 162,994 | -1% | -$131,476 | ||||||
2026-04-01 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Dir | S - Sale | $51.00 | -1,000 | 25,722 | -4% | -$51,000 | ||||||
| D | 2026-04-01 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.20 | -3,500 | 29,375 | -11% | -$7,700 | |||||
| D | 2026-04-01 | CGEN | Compugen Ltd | Ophir Eran | Pres, CEO | S - Sale+OE | $2.21 | -5,625 | 11,375 | -33% | -$12,413 | |||||
| D | 2026-04-02 | KOD | Kodiak Sciences Inc. | Borgeson John A. | CFO | S - Sale+OE | $39.92 | -30,000 | 183,316 | -14% | -$1,197,488 | |||||
| DM | 2026-04-01 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.53 | -38,120 | 447,202 | -8% | -$553,693 | |||||
| DM | 2026-04-01 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $64.81 | -40,000 | 767,780 | -5% | -$2,592,237 | |||||
2026-03-31 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $2.50 | -2,867 | 195,338 | -1% | -$7,168 | ||||||
| D | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $29.46 | -15,000 | 0 | -100% | -$441,904 | |||||
| D | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $29.44 | -2,500 | 12,965 | -16% | -$73,611 | |||||
| D | 2026-04-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $6.31 | -10,946 | 113,856 | -9% | -$69,069 | |||||
2026-04-01 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Chief R, D Officer | S - Sale | $5.26 | -22,598 | 95,961 | -19% | -$118,865 | ||||||
2026-04-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $9.07 | -22,000 | 1,100,391 | -2% | -$199,617 | ||||||
| DM | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $85.43 | -22,240 | 61,202 | -27% | -$1,900,048 | |||||
| DM | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $85.39 | -12,000 | 0 | -100% | -$1,024,660 | |||||
| DM | 2026-03-30 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $22.57 | -50,000 | 1,179,667 | -4% | -$1,128,315 | |||||
| D | 2026-03-30 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $29.34 | -7,500 | 10,503 | -42% | -$220,019 | |||||
2026-03-31 | CRIS | Curis Inc | Kaitin Kenneth I | Dir | P - Purchase | $0.55 | +10,000 | 11,407 | +711% | +$5,487 | ||||||
| DM | 2026-03-27 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $13.14 | -57,180 | 455,878 | -11% | -$751,303 | |||||
| M | 2026-03-27 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.06 | +11,850 | 2,561,850 | 0% | +$60,019 | |||||
| D | 2026-03-26 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.04 | -11,875 | 29,375 | -29% | -$24,187 | |||||
2026-03-27 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $136.82 | -10,000 | 642,567 | -2% | -$1,368,162 | ||||||
| D | 2026-03-26 | SLXN | Silexion Therapeutics Corp | Shirvan Mitchell | CSO, CDO | S - Sale+OE | $1.36 | -22,818 | 27,889 | -45% | -$31,032 | |||||
2026-03-27 | LENZ | Lenz Therapeutics, Inc. | George Jeffrey P. | Dir | P - Purchase | $8.92 | +5,592 | 5,592 | New | +$49,890 | ||||||
2026-03-27 | LENZ | Lenz Therapeutics, Inc. | Schimmelpennink Evert B. | Pres, CEO, Secretary | P - Purchase | $8.95 | +28,089 | 77,289 | +57% | +$251,411 | ||||||
2026-03-27 | LENZ | Lenz Therapeutics, Inc. | Chevallard Daniel R. | CFO | P - Purchase | $8.57 | +7,500 | 12,886 | +139% | +$64,275 | ||||||
2026-03-25 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $85.00 | -2,000 | 179,371 | -1% | -$170,000 | ||||||
| M | 2026-03-24 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.23 | +900 | 274,766 | 0% | +$1,110 | |||||
| D | 2026-03-25 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $95.56 | -37,450 | 54,400 | -41% | -$3,578,821 | |||||
| DM | 2026-03-24 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $14.03 | -57,180 | 468,892 | -11% | -$802,235 | |||||
| M | 2026-03-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.41 | +20,082 | 2,550,000 | +1% | +$108,631 | |||||
| M | 2026-03-23 | SRZN | Surrozen, Inc./De | Tcg Crossover Gp Ii, LLC | 10% | P - Purchase | $24.72 | +121,881 | 736,547 | +20% | +$3,012,768 | |||||
| DM | 2026-03-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $78.02 | -115,977 | 61,202 | -65% | -$9,048,290 | |||||
| D | 2026-03-23 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.25 | -40,000 | 906,556 | -4% | -$130,000 | |||||
| D | 2026-03-23 | VCEL | Vericel Corp | Hagen Heidi | Dir | S - Sale+OE | $32.41 | -15,000 | 31,850 | -32% | -$486,150 | |||||
2026-03-24 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $7.41 | -62,000 | 1,449,695 | -4% | -$459,420 | ||||||
| D | 2026-03-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | VP, Finance, Controller | S - Sale+OE | $8.61 | -390 | 47,055 | -1% | -$3,358 | |||||
| D | 2026-03-23 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $46.78 | -3,182 | 94,308 | -3% | -$148,854 | |||||
| D | 2026-03-23 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $46.78 | -10,020 | 255,501 | -4% | -$468,736 | |||||
| D | 2026-03-23 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $46.78 | -3,708 | 15,565 | -19% | -$173,460 | |||||
2026-03-20 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $66.75 | -2,989 | 83,266 | -3% | -$199,516 | ||||||
2026-03-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale | $9.12 | -7,711 | 61,902 | -11% | -$70,324 | ||||||
2026-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $43.79 | -354 | 137,903 | 0% | -$15,500 | ||||||
2026-03-20 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $43.79 | -297 | 124,104 | 0% | -$13,005 | ||||||
| D | 2026-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $43.79 | -1,742 | 858,887 | 0% | -$76,276 | |||||
| D | 2026-03-20 | BCRX | Biocryst Pharmaceuticals Inc | Heggie Theresa | Dir | S - Sale+OE | $10.11 | -49,933 | 65,352 | -43% | -$504,823 | |||||
| DM | 2026-03-19 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale+OE | $13.46 | -57,180 | 481,906 | -11% | -$769,643 | |||||
| D | 2026-03-20 | KLRS | Kalaris Therapeutics, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale+OE | $6.72 | -1,915 | 0 | -100% | -$12,869 | |||||
| D | 2026-03-20 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $49.10 | -15,000 | 0 | -100% | -$736,439 | |||||
| D | 2026-03-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $79.15 | -2,500 | 0 | -100% | -$197,877 | |||||
| M | 2026-03-18 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.73 | +4,575 | 2,529,918 | 0% | +$26,214 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |